Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing
Reexamination Certificate
2006-01-25
2010-02-09
Ulm, John D. (Department: 1649)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
C424S139100, C435S007100, C435S007950
Reexamination Certificate
active
07658911
ABSTRACT:
A methods, kits and compositions for diagnosing a central nervous system disorder, particularly transient ischemic attack or stroke, comprising measuring the level of NR2A and/or NR2B NMDA receptor or fragment thereof, in a biological sample from a human subject, and optionally measuring other biomarkers such as homocysteine and glutamate. The method is particularly useful for identifying individuals that are at risk for stroke, and for diagnosing stroke in an emergency room setting.
REFERENCES:
patent: 5849895 (1998-12-01), Daggett et al.
patent: 6316611 (2001-11-01), Daggett et al.
patent: 6896872 (2005-05-01), Dambinova
patent: 2005/0181466 (2005-08-01), Dambinova et al.
patent: 2006/0024749 (2006-02-01), Dambinova
patent: WO 02/12892 (2002-02-01), None
patent: WO 2006/081188 (2006-08-01), None
patent: WO 2006/135893 (2006-12-01), None
Dambinova et al. Journal of Stroke and Cerebrovascular Disease, 10: 192 [abstract 194 from The 2001 North American Stroke Meeting].
Izykenova et al. Journal of Stroke and Cerebrovascular Disease, 10: 192 [abstract 195 from The 2001 North American Stroke Meeting].
Greenland et al. Archives of Internal Medicine, 165:2454-2456, Nov. 2005.
Oei et al. Circulation, 111: 570-575, 2005.
DeGiorgio et al., Nature Medicine, 7(11):1189-1193, 2001.
Castillo, J., et al., “Neuroexcitatory Amino Acids and Their Relation to Infarct Size and Neurological Deficit in Ischemic Stroke,”Stroke, 27(6):1060-1065 (Jun. 1996).
Castillo, J., et al., “Progression of ischaemic stroke and excitotoxic aminoacids,”Lancet, 349(9045):79-83 (Jan. 11, 1997).
Dambinova, S.A., et al., “Autoantibodies to Subtypes of Glutamate Receptors as a Hallmarks of Brain Damage: Diagnostic Significance for Paroxysmal Activity and Ischemia,”J. Higher Nervous Activity, 47(2):151-156 (1997) (transl. of:Zh. Vyssh. Nerv. Deiat. Im. I. P. Pavlova, 47(2):439-446 (Mar.-Apr. 1997).
Dambinova, S.A., et al., “Blood test detecting autoantibodies toN-methyl-D-aspartate neuroreceptors for evaluation of patients with transient ischemic attack and stroke,”Clinical Chemistry, 49(10):1752-1762 (2003).
Dambinova, S.A., et al., “Monitoring of Brain Spiking Activity and Autoantibodies to N-Terminus Domain of GluR1 Subunit of AMPA Receptors in Blood Serum of Rats with Cobalt-Induced Epilepsy,”J. Neurochem., 72(3):2088-2093 (Nov. 1998).
Dambinova, S.A., et al., “Multiple panel of biomarkers for TIA/stroke evaluation,”Stroke, 33(5):1181-1182 (May 2002).
Dambinova, S.A., et al., “The presence of autoantibodies to N-terminus domain of G1uR1 subunit of AMPA receptor in the blood serum of patients with epilepsy.”J. Neurological Sciences, 152(1): 93-97 (Nov. 6, 1997).
Davalos, A., et al., “Duration of Glutamate Release After Acute Ischemic Stroke,”Stroke, 28(4): 708-710 (Apr. 1997).
Davalos, A., et al., “Neurological Deterioration in Acute Ischemic Stroke: Potential Predictors and Associated Factors in the European Cooperative Acute Stroke Study (ECASS) 1.”Stroke, 30(12): 2631-2636 (Dec. 1999).
Gahring, L.C.,, et al., “Autoantibodies to Neuronal Glutamate Receptors in Patients with Paraneoplastic Neurodegenerative Syndrome Enhance Receptor Activation,”Molec. Medicine, 1(3): 245-253 (Mar. 1995).
Gray, J.J., et al., “Evaluation of a commercial latex agglutination test for detecting antibodies to cytomegalovirus in organ donors and transplant recipients,”J. Virol. Meth., 16(1-2): 13-19 (May 1987).
Gusev, E.L., et al., “Investigation of the Level of Autoantibodies to Glutamate Receptors in Blood Serum of Patients in Acute Period of Ischemic Stroke,”Zhurnal Nevrologii I Psikhiatrii Imeni S. S. Korsakova; 96(5):68-72 (1996) (in Russian; Abstract in English).
Gusev, E.L., et al., “Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke,”Cerebrovasc. Dis., 10(1):49-60 (Jan.-Feb. 2000).
Hess, S.D., et al.; “Cloning and Functional Characterization of Human Heteromeric N-Methyl-D-Aspartate Receptors,”J. Pharmacol. Exp. Ther., 278(2): 808-816 (Aug. 1996); XP000676640; Abstract.
Hill, M.D., et al., “Biochemical markers in acute ischemic stroke,”Canadian Medical Association Journal,; 162:1139-1140 (Apr. 18, 2000).
Lipton, S.A., et al., “Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor,”Proc. Natl. Acad. Sci. USA, 94(11):5923-5928 (May 27, 1997).
Meldrum, B.S., “Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology,”J. Nutrition, 130:1007S-1015S (2000).
Monyer, H., et al., “Heteromeric NMDA Receptors: Molecular and Functional Distinction of Subtypes,”Science, 256(5060):1217-1221; (May 22, 1992).
Pang, S.C., et al., “Early diagnosis of acute myocardial infarction by myoglobin latex agglutination test,”Jpn. Heart J., 29(5):631-638 (Sep. 1988).
Rogers, S.W., “Autoantibodies to Glutamate Receptor GluR3 in Rasmussen's Encephalitis,”Science, 265(5172):648-651 (Jul. 29, 1994).
Senju, O., et al., “A new immuno quantitative method by latex agglutination—application for the determination of serum C-reactive protein (CRP) and its clinical significance,”J. Clin. Lab. Immunol., 19(2): 99-103 (Feb. 1986).
Skoromets, A.A., et al.; [Autoantibodies to NMDA-type glutamate receptors in the blood of patients with acute ischemic and hemorrhagic stroke]Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova[J. Neurological Sciences], 97(6):53-58 (1997) (In Russian, Abstract in English).
Vila,N., et al., “Plasma homocysteine levels in patients with ischemic cerebral infarction,”Med. Clin. (Barcelona) 110(16): 605-608 (May 9, 1998). (In Spanish) Provided as abstract in English.
Vincent, A., et al., “Pathogenic autoantibodies to neuronal proteins in neurological disorders,”J. Neuroimmunology, 100(1-2):169-180 (Dec. 1999).
Yamamoto, T., et al., “CSF and ECF Gluatmate Concentrations in Head Injured Patients,”Acta Neurochir. [Suppl] 75:17-19 (1999).
U.S. Appl. No. 11/076,974, Dambinova.
U.S. Appl. No. 11/339,440, Dambinova.
U.S. Appl. No. 11/338,447, Dambinova.
U.S. Appl. No. 11/451,679, Dambinova.
Dambinova, et al., “Autoantibodies to Subtypes of Glutamate Receptors as a Hallmarks of Brain Damage: Diagnostic Significance for Paroxysmal Activity and Ischemia.”Journal of Higher Nervous Activity. 1997. vol. 47 (2), pp. 151-156.
Gusev, et al., “Neuroprotective Effects of Glycine for Therapy of Acute Ischaemic Stroke.”Cerebrovasc Dis 2000; 10:49-60.
Dambinova, et al., “Monitoring of Brain Spiking Activity and Autoantibodies to N-Terminus Domain of GluR1 Subunit of AMPA Receptors in Blood Serum of Rats with Cobalt-Induced Epilepsy.”Journal of Neurochemistry, Lippincott-Raven Publishers, Philadelphia.
Dambinova, et al., “The presence of autoantibodies to N-terminus domain of GluR1 subunit of AMPA receptor in the blood serum of patients with epilepsy.”Journal of Neurological Sciences, 152 (1997) 93-97.
Meldrum, B.S., “Glutamate as a Neurotransmitter in the Brain: Review of Physiology and Pathology1.”Journal of Nutrition. 2000; 130:1007S-1015S.
Monyer et al., “Heteromeric NMDA Receptors . . . ”ScienceMay 22, 1992; 256:1217-1221.
Dambinova et al., “Blood Test Detecting Autoantibodies . . . ”Clinical Chemistry2003 49(10); 1181-1182.
Arnall Golden & Gregory LLP
CIS Biotech, Inc.
MacFarlane Stacey
Sullivan Clark G.
Ulm John D.
LandOfFree
Antibody assay methods to assess risk for TIA/stroke does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Antibody assay methods to assess risk for TIA/stroke, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antibody assay methods to assess risk for TIA/stroke will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4178414